Literature DB >> 20599916

Ras inhibition attenuates pancreatic cell death and experimental type 1 diabetes: possible role of regulatory T cells.

Elizabeta Aizman1, Adi Mor, Jacob George, Yoel Kloog.   

Abstract

Regulatory T cells (Treg) play a crucial role in the maintenance of immune homeostasis and prevention of autoimmune diseases. Ras inhibition by 5-fluoro-farnesylthiosalicylic acid (F-FTS) was recently shown to increase the number and boost the suppressive function of Treg, thereby reducing the incidence of experimental diabetes in non-obese diabetic (NOD) mice. To investigate the effect of F-FTS on pancreatic beta cells and the possible involvement of Treg in such an effect, we evaluated the incidence of diabetes and assayed the pancreatic expression of Foxp3, cleaved caspase 3, and Ras-GTP expression in NOD mice treated with different doses of F-FTS. The treated mice showed attenuated progression of experimental diabetes, accompanied by an increase in serum insulin. Daily injections of F-FTS led to an increase in both the number and the migratory capacity of pancreatic Foxp3(+)CD4(+)CD25(+) Treg, while cleaved caspase 3 in the pancreas were significantly decreased, indicating reduced apoptosis. The Treg population induced by F-FTS helped to preserve pancreatic beta-cell viability in the presence of effector T cells. These findings suggest that inhibition of Ras by F-FTS in mice with experimental diabetes upregulates the Treg pool, which infiltrates the pancreas and attenuates the apoptotic cell death of beta cells. It thus appears that F-FTS induces Treg to play a protective role in the progression of experimental type-1 diabetes, suggesting that these cells represent a potential target for the treatment of this disorder. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599916     DOI: 10.1016/j.ejphar.2010.06.029

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  An increase in tolerogenic dendritic cell and natural regulatory T cell numbers during experimental autoimmune encephalomyelitis in Rras-/- mice results in attenuated disease.

Authors:  Avijit Ray; Sreemanti Basu; Nichole M Miller; Andrew M Chan; Bonnie N Dittel
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

Review 2.  Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.

Authors:  Samantha Messina
Journal:  Small GTPases       Date:  2018-09-18

3.  Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.

Authors:  Elizabeta Aizman; Adi Mor; Ayelet Levy; Jacob George; Yoel Kloog
Journal:  Oncotarget       Date:  2012-02

4.  Ras inhibition induces insulin sensitivity and glucose uptake.

Authors:  Adi Mor; Elizabeta Aizman; Jacob George; Yoel Kloog
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

5.  Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells.

Authors:  Morad Zayoud; Victoria Marcu-Malina; Einav Vax; Jasmine Jacob-Hirsch; Galit Elad-Sfadia; Iris Barshack; Yoel Kloog; Itamar Goldstein
Journal:  Front Immunol       Date:  2017-07-07       Impact factor: 7.561

6.  Cassia grandis Lf nanodispersion is a hypoglycemic product with a potent α-glucosidase and pancreatic lipase inhibitor effect.

Authors:  Ariadna Lafourcade Prada; Hady Keita; Tatiane Pereira de Souza; Emerson Silva Lima; Leonard Domingo Rosales Acho; Márcia de Jesus Amazonas da Silva; José Carlos Tavares Carvalho; Jesus Rafael Rodriguez Amado
Journal:  Saudi Pharm J       Date:  2018-10-17       Impact factor: 4.330

Review 7.  Crosstalk between the CBM complex/NF-κB and MAPK/P27 signaling pathways of regulatory T cells contributes to the tumor microenvironment.

Authors:  Tongbing Qi; Ying Luo; Weitong Cui; Yue Zhou; Xuan Ma; Dongming Wang; Xuewen Tian; Qinglu Wang
Journal:  Front Cell Dev Biol       Date:  2022-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.